Australia

The Therapeutic Goods Administration (TGA) is the primary national regulatory authority responsible for evaluating, registering, and monitoring therapeutic goods in Australia, including prescription and over-the-counter medicines, biologicals, medical devices, in vitro diagnostics, and digital health products. The principal governing legislation is the Therapeutic Goods Act 1989, supported by the Therapeutic Goods Regulations 1990 and a suite of classification-specific orders and standards. All therapeutic goods intended for supply in Australia must be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully marketed, with the applicable review pathway determined by product type and risk classification. Medicines follow a tiered registration or listing pathway, while medical devices and diagnostics are classified under a conformity assessment framework aligned broadly with Global Harmonisation Task Force and International Medical Device Regulators Forum (IMDRF) principles. Digital health products may be assessed as Software as a Medical Device (SaMD) under the device framework, and the TGA has issued specific guidance on when software requires ARTG inclusion.

Sponsors seeking to enter the Australian market must appoint a local sponsor, which is an Australian-based legal entity responsible for the product's compliance and post-market obligations. Submission dossiers for prescription medicines are accepted in Common Technical Document (CTD) format, and Australia participates in the ACCESS Consortium and the International Coalition of Medicines Regulatory Authorities (ICMRA), enabling reliance on decisions from comparable overseas regulators such as the US FDA, EMA, Health Canada, and Swissmedic through expedited pathways. The TGA's Priority Review and Provisional Approval pathways are available for products addressing serious or life-threatening conditions with unmet need. In recent years, the TGA has implemented significant reforms under the Regulatory Reform Program, including updates to the device classification rules to align more closely with EU MDR 2017/745, enhanced post-market surveillance obligations, strengthened cybersecurity requirements for connected devices, and expanded provisional approval provisions. Fee structures and guidance documents are regularly updated, making early pre-submission engagement with the TGA strongly advisable.

Australia operates a federated health system in which procurement responsibilities are shared between the Commonwealth Government and eight state and territory governments. The Commonwealth funds and negotiates access to subsidised medicines through the Pharmaceutical Benefits Scheme (PBS), administered by the Department of Health and Aged Care, with pricing and reimbursement recommendations provided by the Pharmaceutical Benefits Advisory Committee (PBAC). Medical devices and diagnostics may be subsidised through the Prostheses List (for private hospital use) or assessed under the Medical Services Advisory Committee (MSAC) process for Medicare Benefits Schedule (MBS) listing, which evaluates clinical safety, effectiveness, and cost-effectiveness. State and territory health departments operate their own hospital procurement frameworks, often coordinating through state health facility networks and shared tendering arrangements such as HealthShare NSW, Health Support Queensland, and the Victorian Government Purchasing Board. The Independent Hospital Pricing Authority (IHPA) sets national efficient prices for admitted and non-admitted hospital services, influencing budget-based procurement decisions at the facility level. Formulary and contract management at the hospital level frequently involves aggregated procurement through state-level panels or standing offer arrangements.

Australia is a high-income country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for domestic health product supply. The private healthcare sector is substantial, with a significant portion of the population holding private health insurance, and private hospitals and pharmacy chains procure products independently through commercial distributors and wholesalers, primarily Sigma Healthcare and EBOS Group. Parallel import provisions exist but are tightly regulated by the TGA. The Commonwealth Government has introduced policies to encourage local sovereign manufacturing capability, particularly following supply chain disruptions highlighted during the COVID-19 pandemic. Initiatives include the Medical Countermeasure Industry Policy, investments through the Medical Research Future Fund (MRFF), and partnerships with domestic manufacturers for vaccines, critical medicines, and personal protective equipment. Preference for locally manufactured products is not formally embedded as a mandatory procurement criterion, but sovereign supply resilience is an increasingly prominent consideration in Commonwealth tender evaluations and strategic purchasing decisions.